Substantial Cost Savings: A Multi-Center Cost Analysis of Nitric Oxide and Epoprostenol Usage in Neonatal Congenital Heart Disease

VentaProst (epoprostenol inhalation) - Aerogen Pharma

https://eppro01.ativ.me/web/page.php?page=IntHtml&project=STS26&id=292408

Darren Turner1; Muhammad Abdullah Shaikh1; Yahia Hejazi1; Kimberley Miles1; Michelle Hudgens1; Jeffrey Alten1; David Cooper1; Paul Critser1; David Morales1

Feb 18, 2026